When to withdraw life support for severe TBI, inflammatory markers score and stroke risk, application overload for neurology residency programs.
In this week's podcast, Neurology Today's editor-in-chief discusses a paper advising against prematurely withdrawing life support for severe TBI, data showing those with the highest composite score of inflammatory markers had a greater risk for stroke, original reporting stressing that residency programs and applicants need to adopt more strategic approaches to managing the overwhelming volume of applications. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
20 Jun 20244min
Code for ICH, new findings on Havana syndrome, distal symmetric polyneuropathy underdiagnosed in low income primary care clinics
In this week's podcast, Neurology Today's editor-in-chief discusses a push among neurocritical care experts to develop a code procedure for intracerebral hemorrhage, new findings showing people with Havana syndrome have functional neurologic disorder, and a study reporting distal symmetric polyneuropathy is more prevalent but less diagnosed in primary care clinics in low-income areas. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
6 Jun 20245min
Surgical removal of hematoma in ICH, disparities in neurodiagnosis for epilepsy, inequities among female neurology researchers
In this week's podcast, Neurology Today's editor-in-chief discusses a new study reporting better outcomes with surgical removal of hematoma in intracerebral hemorrhage, disparities in access to diagnosis and care for epilepsy, and the challenges that remain for women in neurology research.
16 Mai 20244min
Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors' response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.
2 Mai 20244min
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer's disease.
18 Apr 20244min
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
4 Apr 20244min
SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens.
21 Mar 20244min
AI and 911 stroke detection, iatrogenic Alzheimer's and human growth hormone, seizure dogs and refractory epilepsy
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer's, and seizure dogs for refractory epilepsy.
7 Mar 20244min
